Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.
about
Strain-specific viral distribution and neuropathology of feline immunodeficiency virusHIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNAHIV-1 neuroimmunity in the era of antiretroviral therapy.In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesisHIV-1 gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-κB pathway and can be silenced by gp120-specific siRNA.Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDSRodent models for HIV-associated neurocognitive disorders.HIV-1 increases TLR responses in human primary astrocytes.Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation.Early detection of neuropathophysiology using diffusion-weighted magnetic resonance imaging in asymptomatic cats with feline immunodeficiency viral infection.The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.CNS inflammation and macrophage/microglial biology associated with HIV-1 infection.Platelet-activating factor attenuation of long-term potentiation in rat hippocampal slices via protein tyrosine kinase signaling.Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.
P2860
Q30462523-E956EE7C-ED11-4AF8-8636-D1FEFF145959Q31021712-93FD66AE-18A9-4441-9C16-10C46BBD3050Q33733529-7BFBBBD4-7B83-4B7C-BBF4-4F03462DE078Q33749579-F28D9F54-55CA-4345-8675-3A32098AAA6BQ34358241-D5C4E819-C8DC-4E97-8D49-412B4D2342DCQ34504181-3EC9DF24-4C60-492F-B828-9BEDDE1526F0Q34914245-DE941680-8354-480E-BF4E-85C83AC2B487Q35028750-80559462-0C04-4A2B-A2A7-507A092161B8Q35803957-47805A98-0617-4C13-A82C-782529F0AF26Q36376089-F310A6FE-6D12-476E-8B2F-22C30B7E633DQ36441996-63A2EC95-5031-4B1D-AA1F-036FDC36E09AQ37111890-A33FD313-B9BA-4E87-AF8A-E12C8E6759CCQ37324462-288EE5D1-6C94-4106-A9D5-0E4700458B02Q37600700-112B83FB-51F5-497B-8217-386D5DE2BB25Q38512226-6A0C742C-7C68-422B-BCE8-BD04556A3F44Q39404652-C675A4E5-E038-430C-B4F9-1E03FB2717D9
P2860
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of a platelet-acti ...... ated neurocognitive disorders.
@en
Development of a platelet-acti ...... ated neurocognitive disorders.
@nl
type
label
Development of a platelet-acti ...... ated neurocognitive disorders.
@en
Development of a platelet-acti ...... ated neurocognitive disorders.
@nl
prefLabel
Development of a platelet-acti ...... ated neurocognitive disorders.
@en
Development of a platelet-acti ...... ated neurocognitive disorders.
@nl
P2093
P2860
P1476
Development of a platelet-acti ...... ated neurocognitive disorders.
@en
P2093
Chang-Zhi Dong
Dawn Eggert
Francoise Heymans
Harris A Gelbard
Howard E Gendelman
Huanyu Dou
Larisa Poluektova
Nawal Serradji
Pascal Clayette
Prasanta K Dash
P2860
P356
10.1016/J.JNEUROIM.2009.06.002
P577
2009-06-21T00:00:00Z